Xenon Pharmaceuticals Inc.
XENE
Clasificación en acciones
#4395
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company... Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
Precio por acción
$36.06
Última sincronización: 2026-10-21
Capitalización bursátil
$3.49B
Cambio (1 día)
-0.57%
Cambio (1 año)
-14.50%
País
CA
Comercio Xenon Pharmaceuticals Inc. (XENE)
Categoría
Healthcare
Historial del precio de la acción de Xenon Pharmaceuticals Inc. (XENE)
Precio más alto de cierre: $35.96 el 2026-10-01
Precio más bajo de cierre: $13.27 el 2014-11-01
Precio más bajo de cierre: $13.27 el 2014-11-01
Historial del precio de la acción de Xenon Pharmaceuticals Inc. desde 2014 hasta 2026
Desempeño anual del precio de la acción
| Año | Rendimiento |
|---|---|
| 2026 (TTM) | 14.13% |
| 2025 | 9.07% |
| 2024 | -1.96% |
| 2023 | 8.17% |
| 2022 | 36.39% |
| 2021 | 115.16% |
| 2020 | -3.96% |
| 2019 | 105.61% |
| 2018 | 160.68% |
| 2017 | -68.33% |
| 2016 | -4.64% |
| 2015 | -47.01% |
| 2014 | 0.00% |
Precio de la acción de empresas similares o competidoras
| Empresa | Precio de la acción | Cambio 1a% | País |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $757.00 | 7.59% |
CH
|
